&NA;Voriconazole (UK 109496) is a broad spectrum triazole antifungal agent that is in phase III trials with Pfizer in the UK and US for the treatment of resistant systemic candidiasis and invasive aspergillosis. It is also undergoing clinical investigation for oral candidiasis and oesophageal candidiasis.Pfizer hopes to market voriconazole in 2001/2002.Voriconazole is a new triazole antifungal which has a broader spectrum of action than fluconazole and is more potent. Unlike itraconazole, it can be administered either orally or parenterally. Although it may be more effective than currently available triazoles, it has the same problems with drug interactions and adverse events that affect itraconazole.